IgA nephropathy presenting with an atypical nephrotic phenotype in an adolescent: a diagnostic challenge
DOI:
https://doi.org/10.18203/2320-6012.ijrms20263122Keywords:
IgA nephropathy, Nephrotic syndrome, Adolescent, Glomerulopathy, Pleural effusion, Renal biopsyAbstract
IgA nephropathy (IgAN) is the most common primary glomerulopathy worldwide and classically presents with recurrent hematuria, variable proteinuria, and slowly progressive renal impairment. However, atypical presentations mimicking nephrotic syndrome with generalized edema and extrarenal fluid overload are uncommon, particularly in adolescents, posing significant diagnostic challenges. We report the case of a 17-year-old male admitted with progressive facial edema evolving to generalized edema, abdominal distension, dyspnea, and bilateral pleural effusion. Laboratory evaluation revealed subnephrotic-range proteinuria associated with severe nephrotic-like manifestations, including hypoalbuminemia, hypercholesterolemia, microscopic hematuria and hypertension., and transient deterioration of renal function. Initial differential diagnoses included primary nephrotic syndrome, minimal change disease, seronegative autoimmune nephropathy, and secondary glomerular disorders. Autoimmune studies, including antinuclear antibodies (ANA), anti-double stranded DNA, anti-neutrophil cytoplasmic antibodies (ANCA), and anti-glomerular basement membrane antibodies, were negative. Renal biopsy demonstrated mesangial abnormalities consistent with IgA nephropathy, supporting the final diagnosis. The patient received multidisciplinary management with favorable clinical and renal evolution. IgA nephropathy may rarely present with an atypical nephrotic phenotype characterized by severe edema, pleural effusion, and systemic volume overload, particularly in younger patients. Histopathological assessment remains essential for diagnosis in atypical clinical scenarios. This case highlights the importance of considering IgA nephropathy in the differential diagnosis of nephrotic syndrome and underscores the relevance of integrating clinical, laboratory, and histopathological findings. In addition, a focused review of the literature is provided to contextualize uncommon nephrotic presentations of IgAN and their diagnostic implications.
References
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S).
Lai KN, Tang SCW, Schena FP, Novak J, Tomino Y, Fogo AB, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2:16001.
Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91(5):1014-21.
Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22(10):1795-803.
Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402-14.
Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677-86.
Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86(4):828-36.
Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis. 1997;29(6):829-42.
Herlitz LC, Bomback AS, Stokes MB, Radhakrishnan J, D’Agati VD, Markowitz GS. IgA nephropathy with minimal change disease. Clin J Am Soc Nephrol. 2014;9(6):1033-9.
Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002;347(10):738-48.
Barratt J, Rovin BH, Cattran D. Why target the gut to treat IgA nephropathy? Kidney Int Rep. 2020;5(10):1620-4.
Novak J, Rizk D, Takahashi K, Zhang X, Bian Q, Ueda H, et al. New insights into the pathogenesis of IgA nephropathy. Kidney Dis (Basel). 2015;1(1):8-18.
Coppo R. Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients. J Nephrol. 2017;30(3):339-46.
Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318(5):432-42.
Floege J, Amann K. Primary glomerulonephritides. Lancet. 2016;387(10032):2036-48.